HOXC9 and urinary bladder cancer: To further verify the negative role of HOXC9 in responses to immunotherapy, the data from TIDE showed relatively higher HOXC9 was related to worse OS in bladder cancer (P=0.043, Figure 2D), kidney cancer (P=0.027, Figure 2E), and melanoma (P=0.016, Figure 2F) treated with ICIs.